Skip to main content

Articles

Page 4 of 22

  1. Although the heritability of sporadic Alzheimer’s disease (AD) is estimated to be 60–80%, addressing the genetic contribution to AD risk still remains elusive. More specifically, it remains unclear whether gen...

    Authors: Jieun Seo, Min Soo Byun, Dahyun Yi, Jun Ho Lee, So Yeon Jeon, Seong A. Shin, Yu Kyeong Kim, Koung Mi Kang, Chul-Ho Sohn, Gijung Jung, Jong-Chan Park, Sun-Ho Han, Jayoung Byun, Inhee Mook-Jung, Dong Young Lee and Murim Choi

    Citation: Alzheimer's Research & Therapy 2020 12:156

    Content type: Research

    Published on:

  2. Obtaining reliable estimates of the health-related quality of life (HR-QoL) of people with predementia Alzheimer’s disease [AD] (preclinical or prodromal AD), mild cognitive impairment (MCI) and dementia is es...

    Authors: Filipa Landeiro, Seher Mughal, Katie Walsh, Elsbeth Nye, Jasmine Morton, Harriet Williams, Isaac Ghinai, Yovanna Castro, José Leal, Nia Roberts, Helena Wace, Ron Handels, Pascal Lecomte, Anders Gustavsson, Emilse Roncancio-Diaz, Mark Belger…

    Citation: Alzheimer's Research & Therapy 2020 12:154

    Content type: Review

    Published on:

  3. The underlying disease mechanism of neuropsychiatric symptoms (NPS) in dementia remains unclear. Cerebrospinal fluid (CSF) biomarkers for synaptic and axonal degeneration may provide novel neuropathological in...

    Authors: Victor Bloniecki, Henrik Zetterberg, Dag Aarsland, Patrizia Vannini, Hlin Kvartsberg, Bengt Winblad, Kaj Blennow and Yvonne Freund-Levi

    Citation: Alzheimer's Research & Therapy 2020 12:153

    Content type: Research

    Published on:

  4. A consensus protocol for genetic counselling and testing of familial dementia, the Italian Dominantly Inherited Alzheimer’s and Frontotemporal Network (IT-DIAfN) protocol, has been developed in Italy by a netw...

    Authors: Anna Mega, Samantha Galluzzi, Cristian Bonvicini, Silvia Fostinelli, Massimo Gennarelli, Cristina Geroldi, Orazio Zanetti, Luisa Benussi, Emilio Di Maria and Giovanni B. Frisoni

    Citation: Alzheimer's Research & Therapy 2020 12:152

    Content type: Research

    Published on:

  5. TREM2 is a microglial cell surface receptor, with risk mutations linked to Alzheimer’s disease (AD), including R47H. TREM2 signalling via SYK aids phagocytosis, chemotaxis, survival, and changes to microglial act...

    Authors: Hazel Hall-Roberts, Devika Agarwal, Juliane Obst, Thomas B. Smith, Jimena Monzón-Sandoval, Elena Di Daniel, Caleb Webber, William S. James, Emma Mead, John B. Davis and Sally A. Cowley

    Citation: Alzheimer's Research & Therapy 2020 12:151

    Content type: Research

    Published on:

  6. In recent years, mechanistic, epidemiologic, and interventional studies have indicated beneficial effects of omega-3 polyunsaturated fatty acids (n-3 PUFA) against brain aging and age-related cognitive decline...

    Authors: Debora Cutuli, Eugenia Landolfo, Annalisa Nobili, Paola De Bartolo, Stefano Sacchetti, Doriana Chirico, Federica Marini, Luisa Pieroni, Maurizio Ronci, Marcello D’Amelio, Francesca Romana D’Amato, Stefano Farioli-Vecchioli and Laura Petrosini

    Citation: Alzheimer's Research & Therapy 2020 12:150

    Content type: Research

    Published on:

  7. Amyloid β (Aβ)-directed immunotherapy has shown promising results in preclinical and early clinical Alzheimer’s disease (AD) trials, but successful translation to late clinics has failed so far. Compelling evi...

    Authors: Kathrin Gnoth, Anke Piechotta, Martin Kleinschmidt, Sandra Konrath, Mathias Schenk, Nadine Taudte, Daniel Ramsbeck, Vera Rieckmann, Stefanie Geissler, Rico Eichentopf, Susan Barendrecht, Maike Hartlage-Rübsamen, Hans-Ulrich Demuth, Steffen Roßner, Holger Cynis, Jens-Ulrich Rahfeld…

    Citation: Alzheimer's Research & Therapy 2020 12:149

    Content type: Research

    Published on:

  8. We previously found temporoparietal-predominant atrophy patterns in the behavioral variant of Alzheimer’s disease (bvAD), with relative sparing of frontal regions. Here, we aimed to understand the clinico-anat...

    Authors: Ellen H. Singleton, Yolande A. L. Pijnenburg, Carole H. Sudre, Colin Groot, Elena Kochova, Frederik Barkhof, Renaud La Joie, Howard J. Rosen, William W. Seeley, Bruce Miller, M. Jorge Cardoso, Janne Papma, Philip Scheltens, Gil D. Rabinovici and Rik Ossenkoppele

    Citation: Alzheimer's Research & Therapy 2020 12:148

    Content type: Research

    Published on:

  9. Plasma neurofilament light (NFL) and total Tau (t-Tau) proteins are candidate biomarkers for early stages of Alzheimer’s disease (AD). The impact of biological factors on their plasma concentrations in individ...

    Authors: Filippo Baldacci, Simone Lista, Maria Laura Manca, Patrizia A. Chiesa, Enrica Cavedo, Pablo Lemercier, Henrik Zetterberg, Kaj Blennow, Marie-Odile Habert, Marie Claude Potier, Bruno Dubois, Andrea Vergallo and Harald Hampel

    Citation: Alzheimer's Research & Therapy 2020 12:147

    Content type: Research

    Published on:

  10. Alzheimer’s disease (AD) is characterized by progressive memory loss and cognitive impairment. The aggregation of amyloid β (Aβ) and hyperphosphorylated tau protein are two major pathological features of AD. N...

    Authors: Ping Gong, Yan-qing Chen, Ai-hua Lin, Hai-bo Zhang, Yan Zhang, Richard D. Ye and Yang Yu

    Citation: Alzheimer's Research & Therapy 2020 12:146

    Content type: Research

    Published on:

  11. Physical activity has been suggested to prevent the conversion of mild cognitive impairment (MCI) to dementia in patients. We investigated the association between the continuance and regularity of physical act...

    Authors: Yeo Jin Kim, Kyung-Do Han, Min Seok Baek, Hanna Cho, Eun Joo Lee and Chul Hyoung Lyoo

    Citation: Alzheimer's Research & Therapy 2020 12:136

    Content type: Research

    Published on:

  12. Mild cognitive impairment (MCI) is a precursor to Alzheimer’s disease (AD), but not all MCI patients develop AD. Biomarkers for early detection of individuals at high risk for MCI-to-AD conversion are urgently...

    Authors: Daichi Shigemizu, Shintaro Akiyama, Sayuri Higaki, Taiki Sugimoto, Takashi Sakurai, Keith A. Boroevich, Alok Sharma, Tatsuhiko Tsunoda, Takahiro Ochiya, Shumpei Niida and Kouichi Ozaki

    Citation: Alzheimer's Research & Therapy 2020 12:145

    Content type: Research

    Published on:

  13. The eye offers potential for the diagnosis of Alzheimer’s disease (AD) with retinal imaging techniques being explored to quantify amyloid accumulation and aspects of neurodegeneration. To assess these changes,...

    Authors: Sophie Lemmens, Toon Van Craenendonck, Jan Van Eijgen, Lies De Groef, Rose Bruffaerts, Danilo Andrade de Jesus, Wouter Charle, Murali Jayapala, Gordana Sunaric-Mégevand, Arnout Standaert, Jan Theunis, Karel Van Keer, Mathieu Vandenbulcke, Lieve Moons, Rik Vandenberghe, Patrick De Boever…

    Citation: Alzheimer's Research & Therapy 2020 12:144

    Content type: Research

    Published on:

  14. The Amyloid/Tau/Neurodegeneration (ATN) framework has been proposed as a means of evidencing the biological state of Alzheimer’s disease (AD). Predicting ATN status in pre-dementia individuals therefore provid...

    Authors: Catherine M. Calvin, Casper de Boer, Vanessa Raymont, John Gallacher and Ivan Koychev

    Citation: Alzheimer's Research & Therapy 2020 12:143

    Content type: Research

    Published on:

  15. Given the growing older population worldwide, and the associated increase in age-related diseases, such as Alzheimer’s disease (AD), investigating non-invasive methods to ameliorate or even prevent cognitive d...

    Authors: Friederike Thams, Anna Kuzmina, Malte Backhaus, Shu-Chen Li, Ulrike Grittner, Daria Antonenko and Agnes Flöel

    Citation: Alzheimer's Research & Therapy 2020 12:142

    Content type: Research

    Published on:

  16. Possession of the ε4 allele of apolipoprotein E (APOE) is the primary genetic risk factor for the sporadic form of Alzheimer’s disease (AD). While researchers have extensively characterized the impact that APOE ε...

    Authors: Sheina Emrani, Hirra A. Arain, Cassandra DeMarshall and Tal Nuriel

    Citation: Alzheimer's Research & Therapy 2020 12:141

    Content type: Review

    Published on:

  18. The disintegrin metalloproteinase 10 (ADAM10) is the main α-secretase acting in the non-amyloidogenic processing of APP. Some ADAM10 gene variants have been associated with higher susceptibility to develop late-o...

    Authors: Pablo Agüero, María José Sainz, María-Salud García-Ayllón, Javier Sáez-Valero, Raquel Téllez, Rosa Guerrero-López, Julián Pérez-Pérez, Adriano Jiménez-Escrig and Estrella Gómez-Tortosa

    Citation: Alzheimer's Research & Therapy 2020 12:139

    Content type: Research

    Published on:

  19. Impairment in daily functioning is a clinical hallmark of dementia. Difficulties with “instrumental activities of daily living” (IADL) seem to increase gradually over the course of Alzheimer’s disease (AD), be...

    Authors: Mark A. Dubbelman, Roos J. Jutten, Sarah E. Tomaszewski Farias, Rebecca E. Amariglio, Rachel F. Buckley, Pieter Jelle Visser, Dorene M. Rentz, Keith A. Johnson, Michael J. Properzi, Aaron Schultz, Nancy Donovan, Jennifer R. Gatchell, Charlotte E. Teunissen, Bart N. M. Van Berckel, Wiesje M. Van der Flier, Reisa A. Sperling…

    Citation: Alzheimer's Research & Therapy 2020 12:138

    Content type: Research

    Published on:

  20. Lewy body dementia (LBD), including dementia with Lewy bodies and Parkinson’s disease dementia, affects over a million people in the USA and has a substantial impact on patients, caregivers, and society. Sympt...

    Authors: Jennifer G. Goldman, Leah K. Forsberg, Bradley F. Boeve, Melissa J. Armstrong, David J. Irwin, Tanis J. Ferman, Doug Galasko, James E. Galvin, Daniel Kaufer, James Leverenz, Carol F. Lippa, Karen Marder, Victor Abler, Kevin Biglan, Michael Irizarry, Bill Keller…

    Citation: Alzheimer's Research & Therapy 2020 12:137

    Content type: Review

    Published on:

  22. The Multidomain Alzheimer Preventive Trial (MAPT) was designed to assess the efficacy of omega-3 fatty acid supplementation, multidomain intervention (MI), or a combination of both on cognition. Although the M...

    Authors: Julien Delrieu, Thierry Voisin, Laure Saint-Aubert, Isabelle Carrie, Christelle Cantet, Bruno Vellas, Pierre Payoux and Sandrine Andrieu

    Citation: Alzheimer's Research & Therapy 2020 12:134

    Content type: Research

    Published on:

  23. FDG-PET hypermetabolism can be observed in mild cognitive impairment (MCI), but the link to primary pathologies of Alzheimer’s diseases (AD) including amyloid and tau is unclear.

    Authors: Anna Rubinski, Nicolai Franzmeier, Julia Neitzel and Michael Ewers

    Citation: Alzheimer's Research & Therapy 2020 12:133

    Content type: Research

    Published on:

  24. Self-assembly of the amyloid-β (Aβ) peptide into aggregates, from small oligomers to amyloid fibrils, is fundamentally linked with Alzheimer’s disease (AD). However, it is clear that not all forms of Aβ are eq...

    Authors: Lorena De Mena, Michael A. Smith, Jason Martin, Katie L. Dunton, Carolina Ceballos-Diaz, Karen R. Jansen-West, Pedro E. Cruz, Kristy D. Dillon, Diego E. Rincon-Limas, Todd E. Golde, Brenda D. Moore and Yona Levites

    Citation: Alzheimer's Research & Therapy 2020 12:132

    Content type: Research

    Published on:

  25. Early identification of individuals at risk of dementia is mandatory to implement prevention strategies and design clinical trials that target early disease stages. Subjective cognitive decline (SCD) and neuro...

    Authors: Lena Sannemann, Ann-Katrin Schild, Slawek Altenstein, Claudia Bartels, Frederic Brosseron, Katharina Buerger, Nicoleta Carmen Cosma, Klaus Fliessbach, Silka Dawn Freiesleben, Wenzel Glanz, Michael T. Heneka, Daniel Janowitz, Ingo Kilimann, Xenia Kobeleva, Christoph Laske, Coraline D. Metzger…

    Citation: Alzheimer's Research & Therapy 2020 12:131

    Content type: Research

    Published on:

  26. β-Secretase1 (BACE1) protein concentrations and rates of enzyme activity, analyzed in human bodily fluids, are promising candidate biological markers for guidance in clinical trials investigating BACE1 inhibit...

    Authors: Harald Hampel, Simone Lista, Eugeen Vanmechelen, Henrik Zetterberg, Filippo Sean Giorgi, Alessandro Galgani, Kaj Blennow, Filippo Caraci, Brati Das, Riqiang Yan and Andrea Vergallo

    Citation: Alzheimer's Research & Therapy 2020 12:130

    Content type: Review

    Published on:

  27. Lack of awareness of cognitive decline (ACD) is common in late-stage Alzheimer’s disease (AD). Recent studies showed that ACD can also be reduced in the early stages.

    Authors: Federica Cacciamani, Luisa Sambati, Marion Houot, Marie-Odile Habert, Bruno Dubois and Stéphane Epelbaum

    Citation: Alzheimer's Research & Therapy 2020 12:129

    Content type: Research

    Published on:

  28. Cognition is closely associated with physical function. Although high brain amyloid-β (Aβ) deposition and neurofilament light chain (NfL) are associated with cognitive and gait speed decline, relationships of ...

    Authors: Lingxiao He, Philipe de Souto Barreto, Geetika Aggarwal, Andrew D. Nguyen, John E. Morley, Yan Li, Randall J. Bateman and Bruno Vellas

    Citation: Alzheimer's Research & Therapy 2020 12:128

    Content type: Research

    Published on:

  29. White matter hyperintensities (WMH) are very frequent in older adults and associated with worse cognitive performance. Little is known about the links between WMH and vascular risk factors, cortical β-amyloid ...

    Authors: Antoine Garnier-Crussard, Salma Bougacha, Miranka Wirth, Claire André, Marion Delarue, Brigitte Landeau, Florence Mézenge, Elizabeth Kuhn, Julie Gonneaud, Anne Chocat, Anne Quillard, Eglantine Ferrand-Devouge, Vincent de La Sayette, Denis Vivien, Pierre Krolak-Salmon and Gaël Chételat

    Citation: Alzheimer's Research & Therapy 2020 12:127

    Content type: Research

    Published on:

  30. Understanding the earliest manifestations of Alzheimer’s disease (AD) is key to realising disease-modifying treatments. Advances in neuroimaging and fluid biomarkers have improved our ability to identify AD pa...

    Authors: Antoinette O’Connor, Philip S. J. Weston, Ivanna M. Pavisic, Natalie S. Ryan, Jessica D. Collins, Kirsty Lu, Sebastian J. Crutch, Daniel C. Alexander, Nick C. Fox and Neil P. Oxtoby

    Citation: Alzheimer's Research & Therapy 2020 12:126

    Content type: Research

    Published on:

  31. Soluble beta-amyloid (Aβ) can be cleared from the brain through various mechanisms including enzymatic degradation, glial cell phagocytosis, transport across the blood-brain barrier, and glymphatic clearance. ...

    Authors: Weixi Feng, Yanli Zhang, Ze Wang, Hanrong Xu, Ting Wu, Charles Marshall, Junying Gao and Ming Xiao

    Citation: Alzheimer's Research & Therapy 2020 12:125

    Content type: Research

    Published on:

  32. Lysophosphatidic acids (LPAs) are bioactive signaling phospholipids that have been implicated in Alzheimer’s disease (AD). It is largely unknown whether LPAs are associated with AD pathology and progression fr...

    Authors: Shahzad Ahmad, Adelina Orellana, Isabelle Kohler, Lutz Frölich, Itziar de Rojas, Silvia Gil, Mercè Boada, Isabel Hernández, Lucrezia Hausner, Margot H. M. Bakker, Alfredo Cabrera-Socorro, Najaf Amin, Alfredo Ramírez, Agustín Ruiz, Thomas Hankemeier and Cornelia M. Van Duijn

    Citation: Alzheimer's Research & Therapy 2020 12:124

    Content type: Research

    Published on:

  33. Amyloid pathology, which is one of the characteristics of Alzheimer’s disease (AD), results from altered metabolism of the beta-amyloid (Aβ) peptide in terms of synthesis, clearance, or aggregation. A decrease...

    Authors: Sylvain Lehmann, Julien Dumurgier, Xavier Ayrignac, Cecilia Marelli, Daniel Alcolea, Juan Fortea Ormaechea, Eric Thouvenot, Constance Delaby, Christophe Hirtz, Jérôme Vialaret, Nelly Ginestet, Elodie Bouaziz-Amar, Jean-Louis Laplanche, Pierre Labauge, Claire Paquet, Alberto Lleo…

    Citation: Alzheimer's Research & Therapy 2020 12:123

    Content type: Research

    Published on:

  34. There has been ongoing research impetus to uncover novel blood-based diagnostic and prognostic biomarkers for Alzheimer’s disease (AD), vascular dementia (VaD), and related cerebrovascular disease (CEVD)-assoc...

    Authors: Xin Ying Chua, Yuek Ling Chai, Wee Siong Chew, Joyce R. Chong, Hui Li Ang, Ping Xiang, Kaddy Camara, Amy R. Howell, Federico Torta, Markus R. Wenk, Saima Hilal, Narayanaswamy Venketasubramanian, Christopher P. Chen, Deron R. Herr and Mitchell K. P. Lai

    Citation: Alzheimer's Research & Therapy 2020 12:122

    Content type: Research

    Published on:

  35. Cerebrospinal fluid (CSF) amyloid-beta (Aβ) 42/40 ratio, threonine-181-phosphorylated-tau (p-tau), and total-tau (t-tau) represent core biomarkers of Alzheimer disease (AD). The recent availability of automate...

    Authors: Giovanni Bellomo, Samuela Cataldi, Silvia Paciotti, Federico Paolini Paoletti, Davide Chiasserini and Lucilla Parnetti

    Citation: Alzheimer's Research & Therapy 2020 12:121

    Content type: Research

    Published on:

  36. Several studies have investigated the value of alpha-synuclein assay in the cerebrospinal fluid (CSF) of Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) patients in the differential diagnosis of t...

    Authors: Olivier Bousiges, Nathalie Philippi, Thomas Lavaux, Armand Perret-Liaudet, Ingolf Lachmann, Caroline Schaeffer-Agalède, Pierre Anthony, Anne Botzung, Lucie Rauch, Barbara Jung, Paulo Loureiro de Sousa, Catherine Demuynck, Catherine Martin-Hunyadi, Benjamin Cretin and Frédéric Blanc

    Citation: Alzheimer's Research & Therapy 2020 12:120

    Content type: Research

    Published on:

  37. Here, we address a pivotal factor in Alzheimer’s prevention—identifying those at risk early, when dementia can still be avoided. Recent research highlights an accelerated forgetting phenotype as a risk factor ...

    Authors: Alfie R. Wearn, Esther Saunders-Jennings, Volkan Nurdal, Emma Hadley, Michael J. Knight, Margaret Newson, Risto A. Kauppinen and Elizabeth J. Coulthard

    Citation: Alzheimer's Research & Therapy 2020 12:119

    Content type: Research

    Published on:

  38. Blood-based biomarkers for Alzheimer’s disease (AD) might facilitate identification of participants for clinical trials targeting amyloid beta (Abeta) accumulation, and aid in AD diagnostics. We examined the p...

    Authors: Inge M. W. Verberk, Elisabeth Thijssen, Jannet Koelewijn, Kimberley Mauroo, Jeroen Vanbrabant, Arno de Wilde, Marissa D. Zwan, Sander C. J. Verfaillie, Rik Ossenkoppele, Frederik Barkhof, Bart N. M. van Berckel, Philip Scheltens, Wiesje M. van der Flier, Erik Stoops, Hugo M. Vanderstichele and Charlotte E. Teunissen

    Citation: Alzheimer's Research & Therapy 2020 12:118

    Content type: Research

    Published on:

  39. The clinical guidelines related to the primary prevention of Alzheimer’s disease (AD) have focused on the management of vascular risk factors. However, the link between vascular risk factors and AD in older ad...

    Authors: Hyewon Lee, Kiwon Kim, Yeong Chan Lee, Soyeon Kim, Hong-Hee Won, Tae Yang Yu, Eun-Mi Lee, Jae Myeong Kang, Matthew Lewis, Doh Kwan Kim and Woojae Myung

    Citation: Alzheimer's Research & Therapy 2020 12:117

    Content type: Research

    Published on:

  40. Malnutrition is common in patients with Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI) and is associated with institutionalization and increased mortality. Malnutrition is the result of ...

    Authors: Astrid S. Doorduijn, Marian A. E. de van der Schueren, Ondine van de Rest, Francisca A. de Leeuw, Heleen M. A. Hendriksen, Charlotte E. Teunissen, Philip Scheltens, Wiesje M. van der Flier and Marjolein Visser

    Citation: Alzheimer's Research & Therapy 2020 12:116

    Content type: Research

    Published on:

  41. Associations between the frequency of social and intellectual activities and cognitive trajectories are understudied in Chinese middle-aged and older adults. We aimed to examine this association in a nationall...

    Authors: Haibin Li, Changwei Li, Anxin Wang, Yanling Qi, Wei Feng, Chengbei Hou, Lixin Tao, Xiangtong Liu, Xia Li, Wei Wang, Deqiang Zheng and Xiuhua Guo

    Citation: Alzheimer's Research & Therapy 2020 12:115

    Content type: Research

    Published on:

  42. We aimed to investigate the clinical correlates of principal components (PCs) of tau positron emission tomography (PET) and their predictability for longitudinal changes in tau accumulation in Alzheimer’s dise...

    Authors: Hanna Cho, Min Seok Baek, Hye Sun Lee, Jae Hoon Lee, Young Hoon Ryu and Chul Hyoung Lyoo

    Citation: Alzheimer's Research & Therapy 2020 12:114

    Content type: Research

    Published on:

  43. Electrophysiological studies show that reductions in power within the alpha band are associated with the Alzheimer’s disease (AD) continuum. Physical activity (PA) is a protective factor that has proved to red...

    Authors: Jaisalmer de Frutos-Lucas, Pablo Cuesta, Federico Ramírez-Toraño, Alberto Nebreda, Esther Cuadrado-Soto, África Peral-Suárez, David Lopez-Sanz, Ricardo Bruña, Silvia Marcos-de Pedro, María Luisa Delgado-Losada, Ana María López-Sobaler, Inmaculada Concepción Rodríguez-Rojo, Ana Barabash, Juan Manuel Serrano Rodriguez, Simon M. Laws, Alberto Marcos Dolado…

    Citation: Alzheimer's Research & Therapy 2020 12:113

    Content type: Research

    Published on:

  44. There is increasing interest in improving understanding of the timing and nature of early neurodegeneration in Alzheimer’s disease (AD) and developing methods to measure this in vivo. Autosomal dominant famili...

    Authors: Philip S. J. Weston, Teresa Poole, Jennifer M. Nicholas, Nicolas Toussaint, Ivor J. A. Simpson, Marc Modat, Natalie S. Ryan, Yuying Liang, Martin N. Rossor, Jonathan M. Schott, Sebastien Ourselin, Hui Zhang and Nick C. Fox

    Citation: Alzheimer's Research & Therapy 2020 12:112

    Content type: Research

    Published on:

  45. Neurofilament light chain (NfL) is a promising biomarker of neurodegeneration in the cerebrospinal fluid and blood. This study investigated the presence of NfL in the vitreous humor and its associations with a...

    Authors: Manju L. Subramanian, Viha Vig, Jaeyoon Chung, Marissa G. Fiorello, Weiming Xia, Henrik Zetterberg, Kaj Blennow, Madeleine Zetterberg, Farah Shareef, Nicole H. Siegel, Steven Ness, Gyungah R. Jun and Thor D. Stein

    Citation: Alzheimer's Research & Therapy 2020 12:111

    Content type: Research

    Published on:

  46. Sodium oligomannate (GV-971), a marine-derived oligosaccharide, is a novel agent that may improve cognition in AD patients.

    Authors: Tao Wang, Weihong Kuang, Wei Chen, Wenwei Xu, Liming Zhang, Yingjie Li, Hailin Li, Ying Peng, Yangmei Chen, Baojun Wang, Jinsong Xiao, Honghua Li, Chuanzhu Yan, Yifeng Du, Mouni Tang, Zhiyi He…

    Citation: Alzheimer's Research & Therapy 2020 12:110

    Content type: Research

    Published on:

  47. Alzheimer’s disease (AD) mutations in amyloid precursor protein (APP) and presenilins (PSENs) could potentially lead to the production of longer amyloidogenic Aβ peptides. Amongst these, Aβ1–43 is more prone to a...

    Authors: Federica Perrone, Maria Bjerke, Elisabeth Hens, Anne Sieben, Maarten Timmers, Arne De Roeck, Rik Vandenberghe, Kristel Sleegers, Jean-Jacques Martin, Peter P. De Deyn, Sebastiaan Engelborghs, Julie van der Zee, Christine Van Broeckhoven and Rita Cacace

    Citation: Alzheimer's Research & Therapy 2020 12:108

    Content type: Research

    Published on:

  49. Early Alzheimer’s disease (AD) diagnosis is vital for development of disease-modifying therapies. Prior to significant brain tissue atrophy, several microstructural changes take place as a result of Alzheimer’...

    Authors: Alfie R. Wearn, Volkan Nurdal, Esther Saunders-Jennings, Michael J. Knight, Hanna K. Isotalus, Serena Dillon, Demitra Tsivos, Risto A. Kauppinen and Elizabeth J. Coulthard

    Citation: Alzheimer's Research & Therapy 2020 12:105

    Content type: Research

    Published on:

  50. To determine whether performance on the Latin American Spanish version of the Face-Name Associative Memory Exam (LAS-FNAME) can differentiate between cognitively intact carriers of an autosomal dominant Alzhei...

    Authors: Clara Vila-Castelar, Nathalia Muñoz, Kathryn V. Papp, Rebecca E. Amariglio, Ana Baena, Edmarie Guzmán-Vélez, Yamile Bocanegra, Justin S. Sanchez, Eric M. Reiman, Keith A. Johnson, Reisa A. Sperling, Francisco Lopera, Dorene M. Rentz and Yakeel T. Quiroz

    Citation: Alzheimer's Research & Therapy 2020 12:104

    Content type: Research

    Published on:

Submit manuscript

Follow

  • ISSN: 1758-9193 (electronic)

Alzheimer's Research & Therapy

ISSN: 1758-9193